Optiver Holding
ZNTL icon

Optiver Holding’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Optiver Holding’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19 Sell
4
-40
-91% -$160 ﹤0.01% 2712
2026
Q1 		$103 Hold
44
– – ﹤0.01% 2238
2025
Q4 		$59 Hold
44
– – ﹤0.01% 2392
2025
Q3 		$66 Buy
+44
New +$66 ﹤0.01% 2611

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Optiver Holding's ZNTL Position: Q2 2026 in Review

Optiver Holding reduced its Zentalis Pharmaceuticals (ZNTL) stake by 91% in Q2 2026, selling an estimated $160 and leaving 4 shares worth $19. The position accounts for ﹤0.01% of the portfolio, ranked #2712.

Optiver Holding first reported a position in ZNTL in Q3 2025 and has held it in 4 quarters since. The position peaked at $103 in Q1 2026. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Optiver Holding held 4 shares of Zentalis Pharmaceuticals worth $19 as of Q2 2026.
  • Optiver Holding sold 40 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $160.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2712 holding.
  • Optiver Holding first reported a position in Zentalis Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Optiver Holding's Zentalis Pharmaceuticals position peaked at $103 in Q1 2026.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.